PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical

ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA (PV) TREATED WITH BESREMI® (ROPEGINTERFERON ALFA-2B) HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE

PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients

Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft

PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate

PharmaEssentia Included in FTSE Russell Indices

PharmaEssentia and MPN Advocacy & Education International Launch New Educational Initiative to Empower People Living with Polycythemia Vera (PV)

New Study Demonstrates ropeginterferon alfa-2b-njft is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera